Catalent Pharma Solutions has completed the new Development and Analytical Solutions’ laboratories at its facility in Swindon, UK. The new lab suite will offer analytical testing, development support and regulatory services to pharmaceutical and biopharmaceutical companies. Also, the lab suite includes expanded facilities for the storage and testing of controlled and cytotoxic substances.

Additional services offered at the new Swindon labs include European import testing, Qualified Person (QP) and regulatory consulting services, methods development, and microbial, sterility and stability testing for a range of advanced dose forms including for inhaled and orally administered substances.

“This additional capacity, coupled with our international network, means Catalent can offer an unparalleled range and scale of services to the development and testing of large and small molecules,” said Graeme Lowe, director of Analytical Solutions for Catalent in Swindon.

“The enhanced facilities here in Swindon are complimented by Catalent’s acquisitions of Aptuit’s Clinical Trials Supply business and the full ownership of the Eberbach softgel facility. We are now offering a broader range of pharmaceutical and biopharmaceutical testing services from five locations in the US, UK and Germany. We have the expertise and the global reach to help our customers bring more products to market faster,” said Christine Dolan, vice president and general manager of Catalent’s Development and Analytical Solutions.